Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication in Patients With Chronic Pain: an Open-label Feasibility Study

To see complete record on, please visit this link

Id: NCT05585229

Organisation Name: University of British Columbia

Overal Status: Not yet recruiting

Start Date: December 15, 2022

Last Update: October 18, 2022

Lead Sponsor: University of British Columbia

Brief Summary: This is an open-label pilot trial to assess the safety and feasibility of a novel 6-week psilocybin-assisted psychotherapy intervention to facilitate successful tapering/discontinuation of opioid pain medication in adult patients receiving long-term opioid therapy for chronic pain. Participation will last approximately 8 months and includes two 25mg psilocybin-assisted psychotherapy sessions. The study will evaluate the incidence and severity of adverse events during and after treatment, the number of participants who drop out of the study for intervention-related reasons, and the self-reported benefits and harms of the intervention.

  • Opioid Dependence
  • Chronic Pain

Total execution time in seconds: 0.19770288467407